DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Bristol Myers - 2 Revlimid - 2 Eliquis - 2 FactSet - 2 Opdivo - 1 – - 1 Opdualag - 1
Top related locs:
Wednesday's
Top related orgs:
Bristol Myers Squibb - 2 LSEG - 2 Bristol - 2 Pfizer - 2 Bristol Myers - 1 Wall - 1 Medicare - 1 FactSet - 1

Search resuls for: "Opdualag"


3 mentions found


☆ Bristol Myers Squibb results top estimates as new drugs post strong sales growth
  + stars: | 2024-02-02 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +3 min
Bristol Myers Squibb reported quarterly earnings and revenue that topped expectations on Friday as its portfolio of new drugs posted strong sales growth. That group raked in $1.07 billion in sales for the quarter, up 66% from the $645 million for the year-earlier period. While its revenue outlook was in line with Wall Street estimates, it anticipates higher than expected earnings for the year. Analysts surveyed by LSEG expect full-year adjusted earnings of $7 per share and sales growth of 1.9%. Bristol Myers said Eliquis and Opdivo also contributed to the slight sales growth in the fourth quarter.
Persons: Bristol Myers, Revlimid, Eliquis, Opdivo, FactSet Organizations: Bristol Myers Squibb, LSEG, Bristol Myers, Wall, Bristol, Pfizer, Medicare
☆ Bristol Myers Squibb earnings top estimates even as top-selling drug fights generic competition
  + stars: | 2023-10-26 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +3 min
Bristol Myers Squibb on Thursday reported quarterly adjusted earnings that topped expectations and posted revenue in line with estimates, even as sales of the company's popular blood cancer drug Revlimid plummeted due to generic competition. Bristol Myers also reiterated its full-year revenue guidance of a low single-digit percentage decline. Bristol Myers said both older and new drug products helped offset the lower sales of Revlimid for the third quarter. Eliquis, which Bristol Myers shares with Pfizer , is among the first ten drugs selected to face price negotiations with the federal Medicare program. Bristol Myers will hold an earnings call with investors at 8 a.m. E.T.
Persons: Revlimid, Bristol Myers, –, Eliquis, FactSet, Opdualag Organizations: Bristol Myers Squibb, Bristol, LSEG, Pfizer, FactSet, Therapeutics Locations: Wednesday's
☆ A series of mega-blockbuster drugs are on the horizon. How to invest in the trend
  + stars: | 2022-10-08 | by ( Christina Cheddar Berk | ) www.cnbc.com   time to read: +4 min
"That said, the biggest drugs usually feature one, or best case two, of these attributes." Seven drugs on Meacham's list are already in the market, and have already hit the $10 billion or more benchmark. That means some of these drugs may be already hitting the end of their peak sales period. Meacham has previously said that one of the drugs in this bucket, Eli Lilly's tirzepatide, could be the first $100 billion drug . But many investors are hopeful about its potential as an obesity treatment .
0 next >>
Total: 3